Home Health Agency EBITDA Multiples: 3.0x–6.5x — What Buyers Pay (2026)
Medicare-certified home health agencies trade at 3.5x–6x EBITDA. Learn what drives premium valuations and where most lower middle market agencies land.
Home health agencies in the $1M–$5M revenue range typically trade at 3.5x–6x EBITDA, with Medicare certification, clean compliance history, and diversified payor mix driving valuations toward the upper end. Strong CMS star ratings, a stable patient census, and a non-owner-dependent management team are the clearest signals buyers use to justify premium pricing. Agencies burdened by open RAC audits, high staff turnover, or single-referral-source dependency typically trade at or below 4x.
Home Health Agency EBITDA Multiples (2026)
| Practice Size | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed / Below Market | $150K–$300K | 3.0x–3.5x | Open CMS survey deficiencies, unresolved billing audits, heavy owner dependency, or low star ratings. Buyers require significant post-close remediation and price accordingly. |
| Average / Market Rate | $300K–$500K | 3.5x–4.5x | Active Medicare certification, acceptable payor mix, adequate staffing, but limited management depth or moderate referral concentration. Typical SBA-financed transaction range. |
| Above Average | $500K–$750K | 4.5x–5.5x | Strong CMS star ratings, diversified payor mix including private pay or managed care, documented SOPs, and a capable clinical leadership team not reliant on the owner. |
| Premium / Strategic | $750K+ | 5.5x–6.5x | Exceptional outcomes data, multi-county geographic footprint, long-standing hospital referral relationships, and clean compliance history. Primary targets for PE roll-up platforms. |
Valuation Drivers — What Makes Your Multiple Higher or Lower
The spread between 3.5x and 6.5x is not random. These seven factors determine where your firm lands.
CMS Star Rating & Clinical Outcomes
HighAgencies with 4–5 star ratings and low rehospitalization rates command premium multiples. Strong OASIS scores signal clinical quality and reduce post-acquisition compliance risk for buyers.
Payor Mix Diversification
HighHeavy Medicare or Medicaid concentration increases reimbursement risk under PDGM. Agencies with 20–30% private pay or managed care contracts trade at meaningfully higher multiples.
Management Team Independence
HighBuyers heavily discount owner-dependent agencies. A licensed DON, billing manager, and scheduler operating without daily owner involvement can add 0.5x–1.0x to the final multiple.
Clean Compliance & Billing History
HighNo open RAC audits, low claim denial rates, and a third-party billing compliance audit covering three years significantly reduce buyer risk and support higher valuations.
Patient Census Stability
MediumAn active census of 75–150 patients with long average length of service and institutionalized referral relationships demonstrates recurring revenue and reduces post-close attrition risk.
Recent Market Trends
PDGM reimbursement pressure has compressed margins at smaller agencies, pushing some below viable EBITDA thresholds. PE-backed roll-ups remain aggressive acquirers in the 4.5x–6x range for agencies with clean compliance and geographic expansion value. SBA 7(a) financing remains accessible for individual buyers at 3.5x–4.5x, but lenders now require thorough billing compliance documentation pre-approval. Labor cost inflation has become a top diligence concern, with buyers scrutinizing wage rates against regional benchmarks before finalizing offers.
Who Buys Home Health Agencys in 2026
Individual Operator / Search Fund
Entrepreneurship through acquisition (ETA), first-time buyers, industry-adjacent operators
What they want: Stable, transferable cash flow in a Home Health Agency. SBA-eligible business, strong revenue quality, and a seller available for a 12–18 month transition.
Pros for seller
- +SBA 7(a) financing means 10% buyer equity — faster than waiting for institutional capital
- +Buyer works inside the business, maintaining client and staff relationships
- +Deal structure is typically straightforward: cash at close plus seller note
Cons for seller
- −Lower multiples than PE buyers — typically at the low-to-mid end of the range
- −Requires meaningful seller involvement post-close for transition
- −SBA approval timeline adds 60–90 days to closing
PE-Backed Roll-Up Platform
Private equity consolidators building a Home Health Agency portfolio, regional or national platforms
What they want: Scale, operational quality, and geographic coverage. Strong revenue quality with minimal owner dependency. Clean financials, documented systems, and staff who can operate without the selling owner.
Pros for seller
- +All-cash close with no SBA financing contingency or approval delay
- +Highest multiples available for premium businesses
- +Equity rollover option — seller keeps 10–30% stake and participates in platform exit
Cons for seller
- −Extensive 90–150 day due diligence process
- −Post-close integration into a larger platform changes operating culture
- −Usually requires seller to remain in a leadership role for 12–24 months
Strategic Acquirer
Larger Home Health Agency operators, adjacent-industry buyers adding capacity or geography
What they want: Client relationships, staff, and market position that complement existing operations. revenue quality is especially valuable when it fills a gap the buyer cannot build organically.
Pros for seller
- +Can pay above-model multiples for strong strategic fit
- +Buyer already understands the business — diligence moves faster
- +Shorter transition requirement when operational overlap exists
Cons for seller
- −Fewer competing buyers — less negotiating leverage
- −Non-compete scope is typically broader than PE or individual deals
- −Operations and brand may change significantly post-close
Sample Home Health Agency Transactions
Medicare-certified agency in the Southeast, 90 active patients, 4-star CMS rating, diversified payor mix, strong DON in place, no open audits
$420,000
EBITDA
4.8x
Multiple
$2,016,000
Price
Midwest agency with Medicare and Medicaid payor mix, 65 active patients, owner-operator clinical director, moderate compliance documentation, single hospital referral source
$280,000
EBITDA
3.7x
Multiple
$1,036,000
Price
Mid-Atlantic agency with 120+ active patients, managed care contracts, 4.5-star rating, independent management team, acquired by regional PE-backed platform
$690,000
EBITDA
5.8x
Multiple
$4,002,000
Price
EBITDA Valuation Estimator
Get your Home Health Agency business value range instantly
Industry: Home Health Agency · Multiples based on 3.5x–4.5x (Average / Market Rate)
Powered by DealFlow OS
dealflow-os.com · Free M&A tools for every stage of the deal
How to Use These Multiples
For Sellers: 4-Step Valuation Walkthrough
- 1
Compile three years of P&L statements and tax returns that reconcile line by line — SBA lenders and institutional buyers both require this, and any unexplained gap triggers diligence delays or price renegotiation.
- 2
Build a normalized EBITDA schedule with every add-back documented: owner W-2 above a market-rate manager salary, personal expenses, one-time items, and non-recurring costs. Undocumented add-backs get cut.
- 3
Address your owner dependency before going to market — this is the most common reason Home Health Agency businesses receive offers at the low end of the 3x–6.5x range. Buyers identify it in diligence and reprice accordingly.
- 4
Quantify and document your revenue quality with supporting records: contracts, renewal histories, and client revenue breakdowns. This is the primary evidence for commanding a premium multiple — have it ready before the first buyer call.
For Buyers: Validate the Asking Multiple
- 1
Request trailing 12-month and 3-year P&L with bank statement backup before making an offer. If a Home Health Agency seller cannot produce reconciled financials, that signals what the full diligence process will look like.
- 2
Verify the revenue quality claims independently — pull contract copies, renewal documentation, and client-level revenue data. This is the primary driver of whether this Home Health Agency is worth 6.5x or 3x.
- 3
Assess owner dependency directly: ask which revenue or client relationships depend on the current owner personally, and what the transition plan is. An exit-ready seller has already worked through this.
- 4
Model your SBA debt service against verified EBITDA before signing the LOI. At current rates, a $1M SBA 7(a) loan runs approximately $13,000/month over 10 years — the business needs at least 1.25x debt service coverage after a market-rate manager salary.
Frequently Asked Questions
What EBITDA multiple should I expect for my Medicare-certified home health agency?
Most lower middle market agencies sell between 3.5x and 5.5x EBITDA. Clean compliance history, strong CMS star ratings, and management independence are the primary drivers pushing multiples above 4.5x.
How does the CHOW process affect home health agency valuation?
CHOW delays of 60–180 days introduce closing risk. Buyers often structure deals with holdbacks or earnouts tied to successful CMS re-enrollment, which can effectively reduce the net price received at closing.
Can I use an SBA loan to buy a home health agency?
Yes. Home health agencies are SBA 7(a) eligible. Typical structures include 80% SBA financing, 10% seller note, and 10% buyer equity injection, assuming clean financials and no open compliance investigations.
What kills home health agency valuations most often in due diligence?
Open RAC audits, unresolved CMS overpayment demands, high staff turnover, and single-referral-source concentration are the most common value killers discovered during diligence, often triggering price reductions of 20–40%.
More Home Health Agency Guides
Related Reading
Find Home Health Agency businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
No credit card required